Ardelyx Completes Enrollment in Phase 3 ACCEL Trial
The trial was fully enrolled ahead of schedule. Topline data are expected in the second half of 2027.
Related stories
RDACU: trading halted on Nasdaq — volatility pause (9:30 AM ET)
Nasdaq halted trading in RDACU (volatility pause) at 9:30 AM ET.
L impact | EQUITY | Nov 03, 2026, 02:40 PM UTC
Bank Of America Shares Hit 30-week Low
Bank Of America shares decreased to 49.22 USD, the lowest since April 2026. Over the past 4 weeks, Bank Of America lost 8.44%, and in the last 12 months, it decreased 7.69%.
L impact | EQUITY | Nov 03, 2026, 02:31 PM UTC
Dow Jones falls 206.75 points to 51,777.23 after open
M impact | EQUITY | Nov 03, 2026, 02:31 PM UTC
Nasdaq rises 98.65 points, or 0.39 percent, to 25,263.01 after open
M impact | EQUITY | Nov 03, 2026, 02:31 PM UTC
Opera Reports Q3 Revenue Growth of 20%
Opera reported Q3 revenue growth of 20%.
M impact | EQUITY | Nov 03, 2026, 02:31 PM UTC
HID Acquires inepro ID to Expand Secure Print Portfolio
HID acquired inepro ID, expanding its secure print portfolio.
M impact | EQUITY | Nov 03, 2026, 02:31 PM UTC